Related Experiment Video
Updated: May 2, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
13.6K
Riociguat for pulmonary hypertension.
John E Cannon1, Joanna Pepke-Zaba
1Pulmonary Vascular Disease Unit, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK.
Expert Review of Clinical Pharmacology
|March 4, 2014
Summary
Riociguat offers a new treatment approach for pulmonary hypertension, a condition causing right ventricular dysfunction. This review examines riociguat
Area of Science:
- Cardiology
- Pharmacology
- Pulmonology
Background:
- Pulmonary hypertension (PH) is characterized by elevated mean pulmonary artery pressure (≥25 mmHg), leading to right ventricular dysfunction and premature death.
- Current treatments for pulmonary arterial hypertension (PAH) improve exercise capacity but offer limited survival benefits.
- No licensed therapies exist for several other groups of pulmonary hypertension.
Purpose of the Study:
- To review the evidence for riociguat in treating all groups of pulmonary hypertension.
- To focus on riociguat's efficacy in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Main Methods:
- Literature review of clinical studies and trials involving riociguat.
- Analysis of riociguat's mechanism of action: soluble guanylate cyclase (sGC) stimulation.
- Examination of data across different classifications of pulmonary hypertension.
Main Results:
- Riociguat stimulates soluble guanylate cyclase (sGC) independently and synergistically with nitric oxide.
- Evidence suggests potential benefits of riociguat across various PH groups, particularly PAH and CTEPH.
- Further research is ongoing to fully establish riociguat's role in PH management.
Conclusions:
- Riociguat represents a novel therapeutic option for pulmonary hypertension.
- Its unique mechanism targeting sGC offers a new avenue for treatment, especially where other therapies fall short.
- Comprehensive evidence supports riociguat's investigation in PAH and CTEPH, with broader implications for PH treatment.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
817
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
817
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626